News Quantified

PAVM – pavmed inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

PAVmed Subsidiary, Veris Health, Announces Launch of Pilot Program with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Carpal Tunnel Syndrome Market Size to Worth USD 1,328.69 Mn by 2032 [Yahoo! Finance]

PAVmed Inc. (NASDAQ: PAVM) was upgraded by analysts at Lake Street Capital to a "strong-buy" rating.

PAVmed Non-GAAP EPS of -$0.99 beats by $0.56, revenue of $1.01M misses by $0.03M [Seeking Alpha]

PAVmed Provides Business Update and First Quarter 2024 Financial Results

Lake Street Capital

Form 8-K PAVmed Inc. For: May 14

Form 10-Q PAVmed Inc. For: Mar 31

Form 8-K PAVmed Inc. For: May 01

Form 8-K PAVmed Inc. For: Apr 30

Form DEFA14A PAVmed Inc.

Top News Gainers

3/24 PAVmed to Hold Business Update Conference Call on April 9, 2020 19.1%

3/30 Form NT 10-K PAVmed Inc. For: Dec 31 14.5%

4/9 PAVmed Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update 14.2%

2/11 U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test 14.2%

4/21 PAVmed Receives FDA 510(k) Clearance for its CarpX™ Minimally Invasive Carpal Tunnel Device 11.5%

6/25 Form 8-K PAVmed Inc. For: Jun 25 10.6%

12/13 PAVmed Provides Update on CarpX™ Clinical Safety Study 9.4%

3/9 Form 8-K PAVmed Inc. For: Mar 09 8.9%

5/22 Form S-8 PAVmed Inc. 7.8%

3/2 PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients 7.1%

Top News Decliners

1/13 PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance -15.5%

11/5 PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization -12.5%

11/7 Form D PAVmed Inc. -10.9%

3/3 PAVmed Inc (NASDAQ: PAVM) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -10.2%

2/27 PAVmed Inc (NASDAQ: PAVM) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $5.00 price target on the stock. -8.3%

4/18 PAVmed Inc (NASDAQ: PAVM) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $5.00 price target on the stock. -7.7%

5/21 PAVmed Reports First Quarter 2019 Financial Results and Provides Business Update -6.8%

6/24 PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™ -6.1%

5/1 Form 8-K PAVmed Inc. For: Apr 30 -6.0%

5/8 Form 424B5 PAVmed Inc. -5.9%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day